CytRx Receives FDA Letter Regarding Arimoclomol Phase IIb Clinical Trial For ALS

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced its intention during the 2009 fourth quarter to submit a revised protocol for its planned Phase IIb clinical trial for arimoclomol as a treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The decision follows receipt of an anticipated written letter from the U.S.
This entry was posted in News from Other Sources. Bookmark the permalink. Both comments and trackbacks are currently closed.